140 likes | 415 Views
Cyto Pulse Sciences, Inc. A Medical Device and Treatment Development Company. 25 June 2009. Instruments - Therapeutic Production Medical Devices - DNA Vaccine Delivery. 0621. Business Areas. Instruments - Produce/Discover Therapeutics More than 40 Revenue Producing Licenses in Place
E N D
Cyto Pulse Sciences, Inc A Medical Device and Treatment Development Company 25 June 2009 Instruments - Therapeutic Production Medical Devices - DNA Vaccine Delivery 0621
Business Areas • Instruments - Produce/Discover Therapeutics • More than 40 Revenue Producing Licenses in Place • Growing 40% per year • Development Stage Medical Devices • Deliver DNA/RNA Therapy • Focus on cancer treatment and infectious diseases • Clinical trials in progress • Looking for partners to license
Hybrimune™ mAb Discovery InstrumentA number have multiple licenses Others in negotiation
Large Volume Cyto LVT-P™Therapeutic Production Instrument • Closed sterile transfection system • One 23 minute run produces product for 50k to 100k human vaccine doses • Vaccine production begins fall 2009 • Partner-AlphaVax Human Vaccines • Novartis licenses CMV vaccine(press release 28 Dec 2008) • $20 million payment to AlphaVax • Expected to enter Phase II in 2009
Derma Vax™ – DNA Intradermal Delivery Cancer Immunotherapy Medical Device • Delivery Process • Insert therapetic into skin using hypodermic needle • Insert electrode into skin (2 mm) • Apply voltage waveform (1/3 second) • Waveform generator • Touch screen user input • Computer controlled • Compliance Certified • Electrode single use, sterile and disposable
Clinical Trials - Phase I • 8 Cancer academic collaboratorsLymphoma, prostate, colorectal, breast • 15 Infectious Disease academic collaboratorsHIV, Flu, Hep B, Hep C Need Partners
Easy Vax™ DNA Epidermal DeliveryProphylactic (infectious diseases) System Operation • Load coated array • Insert array into skin • DNA comes off needles • Electric field delivers DNA battery • Sponsor NIAID $5 million • Dengue 4 serotype vaccine • Tested with smallpox (mice) • Human tolerability trial
Easy Vax™ – Current StatusMice and Monkeys - dengue Monkey Response needs optimization
Cyto Pulse Sciences, Inc. • Incorporated 1995 • Maryland C Corp • 15 Employees • Engineers • Biologists • 94 approved vendors • Products in production • Quality & Design Control System • FDA CFR-820 • EU MDD • No institutional investors Headquarters Glen Burnie, MD, USAStockholm, Sweden – Tokyo, Japan
Leadership Team • Management • Richard Walters, BSE, MSEE, MBA, Founder CEO • Alan King, DVM, PhD, Founder VP • Derin Walters, BSE, MBA VP Asian Operations • John B. Burke, MBA, CPA CFO • Anna-Karin Roos, PhD Mgr EU Operations • Board of Directors • Richard Walters Chairman • Harold Chappelear, BS Pharma (former EVP Upjohn) • Daniel Rak, JD • Stephen Schimpff, MD (former CEO UMMC) • Scientific Advisory Board (SAB) • Stephen Schimpff, MD Chairman • Judith Karp, MD, Oncology JHU Med School • Ruben Mezrich, MD, PhD EE, Radiology UM Med School • Carol Tacket, MD, UM Center for Vaccine Dev UM Med School
Thank you to Larta for the Opportunity • Will be around conference and available for discussions